Клиническая фармакология в здравоохранении, образовании и науке

Эта публикация является переводом единственной оригинальной официальной версии, опубликованной на английском языке. Перевод сделан Всероссийской ассоциацией клинических фармакологов.

Данный меморандум посвящён вкладу клинической фармакологии в здравоохранение, образование и науку. Он был составлен и отредактирован представителями Международного объединения по общей и клинической фармакологии (IUPHAR), Всемирной организации здравоохранения (ВОЗ) и Международного совета медицинских научных организаций (CIOMS). Он представляет собой обновленную и отредактированную версию недавней работы «Клиническая фармакология в науке, образовании и здравоохранении — взгляд IUPHAR, Международного объединения по общей и клинической фармакологии», которая была опубликована в «Журнале общей и клинической фармакологии и токсикологии» (BСPT) в 2010, том 107, страницы 531–559. Этот документ содержит новые главы, имеющие особую значимость для глобального здравоохранения.

1. Clinical Pharmacology. Scope, Organisation, Training. Report of a WHO Study group. World Health Organ. Tech.Rep.Ser 1970;446:5–21.

2. World Health Organisation. Guidelines for the Development of National Drug Policies. World Health Organisation, Geneva, 1988.

3. McKenney JM, Harrison WL. Drug-related hospital admissions. Am J Hosp Pharm 1976;33:792-5.

4. Wester K, Jonsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008;65:573-9.

5. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18,820 patients. Brit Med J 2004;329:15-19.

6. Aronson JK. Medication Errors: what they are, how they happen and how to avoid them. QJM 2009;102:513-21.

7. Aronson JK. Clinical Pharmacology and Therapeutics in the UK – a great instauration. Br J Clin Pharmacol 2010;69:111-7.

8. Horton R. The UK’s NHS and pharma: from schism to symbiosis. Lancet 2009;373:435-6

9. World Health Organisation. Rational Use of Medicines. http://www.who.int/medicines/area/rational_use/en/index.html (last accessed April 8th 2012).

10. Dollery CT. Clinical Pharmacology, the first 75 years and a view of the future. Br J Clin Pharmacol 2006;61:650-5.

11. Sjöqvist F. An historical perspective on the development of clinical pharmacology in the world. In Ref Desarollo de la farmacologia clinica en Espana. Editor Pedro Sanchez Garcia.Real Academica Nacional de Medicina, 2011;Madrid pp 15- 23.

12. Shelley JH, Baur MP. Paul Martini: the first clinical pharmacologist? Lancet 1999;353:1870-3

13. Lasagna L. Clinical Pharmacology: Present Status and Future Development. Science 1966;15:388-91.

14. Lasagna L. Clinical pharmacology in the United States: a personal reminiscence. Ann Rev Pharmacol Toxicol 1985;25:27-31.

15. Kalow W. Pharmacogenetics. In: COWS, editor. Philadelphia; 1962.

16. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 1957;165:835-7.

17. Dangoumau J. [The origins of clinical pharmacology in France].Therapie 2002;57:626.

18. Clinical Pharmacology. The European challenge. WHO Regional Publications, European Series 1991;No 39.

19. Food and Drug Administration. Challenge and opportunity on the critical path to new medicinal products. Bethesda: US Department of Health and Human Services, 2004.

20. European Medicines Agency. The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future. EMEA/H/34163/03/Final.

21. Anon. Triple therapy. The Economist. Aug 14th 2008. http://www.economist.com/people/displaystory.cfm?story_id=11919385 (last accessed April 25th 2012).

22. Blaschke TF. Global challenges for clinical pharmacology in the developing world. Clin Pharmacol Ther 2009;85:579-81.

23. Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profitsmarket exclusivity for biologics. N Engl J Med 2009;361:1917-9.

24. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H et al. Bridging the efficacy-efficiency gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 2011;10: 495 – 506.

25. Godman B, Shrank W, Anderson M, Berg C,Bishop I, Burkhardt T et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:707-22

26. Sjöqvist F, Bergman U, Dahl ML, Gustafsson L, Hensjö LO . Drug and therapeutics committees: a Swedish experience. Drug Inf J 2002;16:207-13.

27. Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselström J et al. The “Wise List” – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33.

28. Breckenridge A, Woods K, Walley, T. Medicines regulation and health technology assessment. Clin Pharmacol Ther 2010;87:152-4.

29. Reidenberg MM. Can the selection of essential medicines decrease inappropriate drug use. Clin Pharmacol Ther 2009;85:581-3.

30. Crooks J. Drug epidemiology and clinical pharmacology: their contribution to patient care. Br J Clin Pharmacol 1983;16:351-7.

31. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet 2003:362;1225-30.

32. Clinical Pharmacological Services. Report of a working group, Bonn. April 26-29 1977. WHO Regional Office for Europe.

33. Jonsson CO, Mårtens S, Sjöqvist F. Evaluation of clinical trials of drugs – particularly psychotropic drugs. Nordisk Psykiatrisk Tidskritft 1969;23:281-9. (In Swedish)

34. World Health Organisation. The selection of essential drugs: report of a WHO Expert Committee. Technical Report series no 615. World Health Organisation, Geneva 1977.

35. Introduction to Drug Utilization Research. World Health Organisation, Geneva, 2003.

36. Soumerai SB, Avorn J. Principles of educational outreach (“academic detailing”) to improve clinical decision making. JAMA 1990;263:549-56.

37. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf 2001;24:1-7.

38. Holloway K. Irrational use of medicines: Global challenges and actions. World Health Organization, Harvard Medical School and Harvard Pilgrim Health. Medicines use in Primary Care in Developing Countries and Transitional Countries: Fact Book Summarizing Results from Studies Reported between 1990 and 2006.World Health Organization, Geneva, 2009.

39. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009;13:1-9.

40. Eklöf A, Thurelius A, Garle M, Rane A, Sjöqvist F. The anti-doping hot-line, a means to detect and prevent the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 2003;59:571-7.

41. Wu LT. Substance abuse and rehabilitation: responding to the global burden of diseases attributable to substance abuse. Subst Abuse Rehabil 2010:1;5-11.

42. Sjöborg B, Bäckström T, Arvidsson LB, Andersen-Karlsson E, Blomberg LB, Eiermann B, et al. Design and implementation of “point of care” computerised system for drug therapy in Stockholm metropolitan health region – bridging the gap between knowledge and practice. Int J Med Inform 2007;76:497-506.

43. Böttiger Y, Laine K, Andersson ML et al. Sfinx – a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009;65:627-33.

44. Bonati M, Breitkreutz J, Choonara I, Hoppu K, Jacqz-Aigrain E, Langhendries J-P et al. Paediatric Clinical Pharmacology in Europe. Paed Perinatal Drug Ther 2006;7:134-7.

45. Boréus LO . Principles of Pediatric Pharmacology. 1982:193-204. Churchill Livingston, New York

46. Choonara I, Dewit O, Harrop E, Howarth P, Helms D, Kanabar W et al. Training in Paediatric Clinical Pharmacology in the UK. Br J Clin Pharmacol 2004;58:217-8.

47. World Population Ageing: 1950-2050, United Nations, New York,2001. www.un.org/esa/population/publications/worldageing19502050/ (accessed 10 April 2012).

48. Abernethy DR. Drug Therapy in the Elderly. In Principles of Clinical Pharmacology, 2nd edition, AJ Atkinson, DR Abernethy, CE Daniels, PL Dedrick, SP Markey Eds. Academic Press, New York, 2007, Chapter 24, pp 375-88.

49. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76.

50. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56.

51. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24.

52. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007;167:781-7.

53. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases. JAMA 2005;294:716-24.

54. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004;351:2870-4.

55. Dean B, Schachter M, Vincent C, Barber N. Causes of prescribing errors in hospital inpatients: a prospective study. Lancet 2002;359:1373-8.

56. Flockhart DA, Usdin YS, Pezzullo JC, Knollman BC.Teaching rational prescribing: A new clinical pharmacology curriculum in medical schools. Naunyn Schmiedebergs Arch Pharmakol 2002;366:33-43.

57. Gwee MC. Teaching of medical pharmacology: the need to nurture the early development of desicured attitude for safe and rational drug prescribing. Med Teach 2009;31:847-54.

58. Heaton A, Webb DJ, Maxwell SRJ. Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates. Br J Clin Pharmacol 2008;66:128-34.

59. Smith A, Tasioulas T, Cockayne N, Misan G, Walker G, Quick G. Construction and evaluation of a web-based interactive prescribing curriculum for senior medical students. Br J Clin Pharmacol 2006;62:653-9.

60. Maxwell SRJ, McQueen DS, Ellaway R. eDrug: a dynamic interactive electronic drug formulary for medical students. Br J Clin Pharmacol 2006;62:673-81.

61. Rawlins MD. ‘De Testimonio’. www.rcplondon.ac.uk/pubs/contents/304df931-2ddc-4a54-894e-e0cdb03e84a5.pdf (last accessed April 12th 2012).

62. Grabowski H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 2008;7:479-88.

63. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HGM, Egberts ACG. Safety-related regulatory actions for biologicals approved in the United States and the European Union. J Am Med Ass. 2008;300:1887-96.

64. Frank RG. Regulation of follow-on biologics. N Engl J Med 2007;357:841-3.

65. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N et al. Pure redcell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8.

66. Gottlieb S. Biosimilars: policy, clinical and regulatory considerations. Am J Health Syst Pharm 2008;65:S2-S8.

67. Roger SD, Goldsmith D. Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther 2008;33:459-64.

68. Declerck PJ. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 2007;30:1087-92.

69. Lewis P. The clinical pharmacologist in drug discovery and development. Br J Clin Pharmacol 1996;42:133-6.

70. Vane J, O’Grady J. Clinical pharmacology in the pharmaceutical industry. Br J Clin Pharmacol 1991;31:155–7.

71. Baber NS. The scope of clinical pharmacology in the pharmaceutical industry. Br J Clin Pharmacol 1991;31:495–6.

72. International ethical guidelines for biomedical research involving human subjects. The Council for International Organizations of Medical Sciences (CIOMS) Geneva, 2002 Web site: http://www.cioms.ch/publications/frame_available_publications.htm (Last accessed April 25th 2012) ( ISBN 92 9036 075 5).

73. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series, No. 850, 1995, Annex 3, World Health Organization. Web site: http://apps.who.int/medicinedocs/en/q (last accessed May 9th 2012).

74. International conference of harmonization (ICH) E6: Good Clinical Practice: Consolidated Guideline. Web site: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html (Last accessed May 9th 2012).

75. WHO Policy Perspective on Medicines No 7 “Effective Medicines Regulation: Ensuring Safety, Efficacy and Quality”, November 2003, World Health Organization. Web site: http://www.who.int/medicines/publications/policyperspectives/en/ Or http://apps.who.int/medicinedocs/en/q (last accessed May 9th 2012).

76. EMA Mission Statement. Web site: http://www.ema.europa.eu/ema/index.jsp (Last accessed April 12th 2012).

77. Smith AJ, McGettigan P. Quality use of medicines in the community: the Australian experience. Br J Clin Pharmacol 2000;50:515–9.

78. Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics and electronic health records: a feasibility study. J Am Med Inform Assoc 2009;Mar 4.

79. Lesko LJ. Paving the Critical Path: How can Clinical Pharmacology help achieve the Vision? Clin Pharmacol Ther 2007;81:170–7.

80. Massol J, Puech A, Boissel JP. How to anticipate the assessment of the public health benefit of new medicines? Therapie 2007;62:427-35.

81. World Health Organisation 2002. What is traditional medicine? In: Traditional Medicine Strategy 2002-2005. WHO, Geneva.

82. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). New Engl J Med 2000;342:1686-92.

83. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ying Ruan, Jun-Shen Wang et al. Effect of St John’s Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.

84. Rieger K, Scholer A, Arnet I, Peters FT, Maurer HH, Walter-Sack I et al. High prevalence of unknown co-medication in hospitalised patients. Eur J Clin Pharmacol 2004;60:363-8.

85. Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: A qualitative study in women with breast cancer. J Fam Prac 1999;48:453-8.

86. World Health Organisation 1999 WHO monographs on selected medicinal plants volume 1, WHO, Geneva.

87. World Health Organisation 2002.WHO monographs on selected medicinal plants volume 2, WHO, Geneva.

88. World Health Organisation 2007. WHO monographs on selected medicinal plants volume 3, WHO, Geneva.

89. Cochrane Reviews. http://www2.cochrane.org/reviews/en (last accessed April 11th 2012).

90. University of Washington. Evidence-based mini-reviews: Important herbs and supplements for physicians to know about. http://books.google.co.za/books?id=O8igGwAACAA J&source=gbs_navlinks_s (last accessed April 27th 2012).

91. Jones JL. AMSA develops CAM curriculum for US medical schools. http://jacquelineljones.com/amsa-develops-camcurriculum-for-us-medical-schools.htm. (last accessed April 11th 2012).

92. The Institute of Chinese Medicine, the Chinese University of Hong Kong. http://www.icm.cuhk.edu.hk/icm/en/index.htm. (last accessed April 11th 2012).

93. South African Traditional Medicines Research Group. Medicinal Plant Monographs. http://www.plantzafrica.com/medmonographs/index.html (accessed April 11th 2012).

94. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White, NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2004 ;2(4):e100.

95. WHO-UMC database of Adverse Drug Reactions. http://www.who-umc.org/ (last accessed April 27th 2012).

96. United Nations High Commissioner for Human Rights. Universal Declaration of Human Rights, 1948. Accessed through http://donegallpass.org/UNIVERSAL_DECLARAT ION_OF_HUMAN_RIGHTS.pdf (last accessed April 25th 2012).

97. Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L. Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts? Lancet 2006;368:305-11.

98. The World Bank, Data and Statistics, 2005 International Comparison Program - Results. www.worldbank.org/data/icp (last accessed April 11th 2012).

99. Laing R., Hogerzeil HV, and Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan 2001;16:13-20.

100. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.

101. Fraser HS. Clinical pharmacology in developing countries. Br J Clin Pharmacol 1981;11:457-9.

102. Richens A, Routledge P. Essentials of clinical pharmacology for education and research in developing countries. Br J Clin Pharmacol 1984;18:123-26.

103. Folb PI. The future of clinical pharmacology in South Africa. CME 1991;9:1485-90.

104. Mucklow J. Postgraduate education in clinical pharmacology and therapeutics. Br J Clin Pharmacol 1998;45:339-46.

105. Royal College of Physicians. Specialty training curriculum for clinical pharmacology and therapeutics. Joint Royal Colleges of Physicians Training Board. Oct 2009.

106. Gray J, Lewis L, Nierenberg D. Clinical pharmacology education in primary care residency programs. Clin Pharmacol Ther 1997;62:237-40.